Creating Value For Our Shareholders

Why Invest in Bayer

Report Highlights

q3-2022-ogimage

Quarterly Statement Third Quarter 2022

Investment Case

Event Highlights

Hands_with_smartphone

November 8, 2022

Investor Conference Call

Q3 2022 Results

CH Webinar_Teaser

September 15, 2022

Consumer Health Investor Webinar September 2022

PH_Asundexian_Header

August 29, 2022

Asundexian Investor Webinar August 2022

Girl using a drone with the sunset in the background

August 11, 2022

Crop Science Field Technology Showcase

Hands_with_smartphone

Investor Conference Call

Q2 2022 Results

enhancing-transparency

Enhancing Transparency: Bayer’s UN Global Compact adherence Webinar

Investor Conference Call

Q1 2022 Results

Werner Baumann & Norbert Winkeljohann

Virtual Event: Annual Stockholders’ Meeting 2022

VIEW ALL EVENTS

News from Bayer

November 11, 2022

Not intended for U.S. and UK Media

Bayer receives positive CHMP opinion for Eylea™ in the EU for treatment of preterm infants with retinopathy of prematurity

November 08, 2022

Third quarter of 2022

Bayer with continued strong performance

October 17, 2022

Not intended for U.S. and UK Media

Bayer expands development program for elinzanetant with Phase III study in breast cancer patients with vasomotor symptoms caused by endocrine therapy

Sustainability & Governance

Our Commitment to Sustainability

Discover More Investor Resources

Returning Value to Shareowners

Detailed Insight into Debt & Fixed Income

Business man pointing on rising graph

Discover Our Interactive Stock Charts

CORPORATE GOVERNANCE

Managing and Supervising an Enterprise

CONTACT IR TEAM

Get In Touch With Us

Subscribe To Our Latest Investor News

USES AND SAFETY RECORD

Let’s Talk About Glyphosate

Learn About The Litigation

Glyphosate Litigation Facts